Analyst firms · Oppenheimer · PRCT
Oppenheimer PRCT price target and rating history
PROCEPT BioRobotics Corporation (PRCT) · Health Care
Oppenheimer rates PROCEPT BioRobotics Corporation (PRCT) Perform with a $60 price target, as of its latest action on Feb 26, 2026. It has published 3 rating actions on PRCT since July 2025, including 1 upgrade and 1 downgrade. Across 8 firms with a PRCT price target in the last 12 months, the median target is $27.
- Current rating
- Perform
- Price target
- $60
- Median target, all firms
- $27
- Actions on PRCT
- 3
Every Oppenheimer rating on PRCT
- Feb 26, 2026
- Sep 2, 2025
- Jul 7, 2025
How other firms rate PRCT
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Barclays | Overweight | $30 | Oct 7, 2026 |
| William Blair | Mkt Perform | Aug 5, 2026 | |
| Wells Fargo | Equal Weight | $19 | Aug 5, 2026 |
| UBS | Neutral | $20 | Jul 28, 2026 |
| Truist Securities | Hold | $25 | Jul 6, 2026 |
| Evercore ISI | Outperform | $30 | Jun 24, 2026 |
| Leerink Partners | Market Perform | $29 | Jun 11, 2026 |
| Robert W. Baird | Neutral | $30 | Mar 6, 2026 |
| Oppenheimer | Perform | Feb 26, 2026 | |
| BofA Securities | Underperform | $20 | Feb 26, 2026 |
Questions about Oppenheimer and PRCT
- What is Oppenheimer's price target for PRCT?
- Oppenheimer's latest stated price target for PROCEPT BioRobotics Corporation (PRCT) is $60, from its action on Sep 2, 2025.
- What is Oppenheimer's rating on PRCT?
- Oppenheimer rates PRCT Perform, a neutral rating, as of Feb 26, 2026.
- When did Oppenheimer last change its view on PRCT?
- On Feb 26, 2026, Oppenheimer downgrades to Perform from Outperform.
- How does Oppenheimer's PRCT target compare with other analysts?
- Across 8 firms with a PRCT price target in the last 12 months, the median target is $27.
More PRCT rating histories
All Oppenheimer ratingsPRCT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.